Business
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding i
About this update from Cytomed Therapeutics Limited
[{"type":"image","alt":"CYTOMED THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"CYTOMED THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":139,"url":"https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kZfTE6ya73voiEtLPclhmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e","width":300,"height":139}},"lazy":false},{"type":"text","content":"SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding in the Company through recent open-market purchases of 105,824 shares. This is on top of 187,500 shares which he holds personally, bringing his personal stake in CytoMed to 2.50% as of today. In addition, our Chairman is also a 55% shareholder of Glorious Finance Limited, and the sole shareholder of EP Capital Inc, representing 2,282,422 shares, or 19.45% of the Company. In aggregate, he owns 2,388,246 shares representing 21.95% of the Company’s total outstanding shares.","length":974,"tagName":"p"},{"type":"text","content":"On his purchases, Chairman Peter remarked "I see value and potential in our novel proprietary technologies to treat cancers in an affordable and “off-the-shelf” manner amidst rising investors’ interest in biotherapeutics in Asia, especially China. In addition, Southeast Asia’s expanding healthcare and medical travel ecosystem, coupled with the rising cost of healthcare in the West, present unique opportunities to those who can innovate and provide cost-competitive patient access. The region’s accelerating biotech momentum, M&A opportunities and supportive regulatory environment further reinforces my purchase decision.”","length":635,"tagName":"p"},{"type":"text","content":"The Company will provide updates on further purchases by our Chairman and will announce when availabl...